Antiplatelet therapy in (cardio)vascular disease
暂无分享,去创建一个
J. Rogers | F. Dudbridge | A. Coffey | P. Bray | J. Emmerich | J. Zwaginga | P. Gaussem | S. Bray | P. Burns | C. Hackeng | R. Fijnheer | A. Veyradier | Goodall Ah | Eikenboom Jc | Philippa Burns
[1] J. T. ten Berg,et al. The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up , 2011, Thrombosis and Haemostasis.
[2] J. T. ten Berg,et al. A case–control study on platelet reactivity in patients with coronary stent thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.
[3] V. Deneer,et al. Esomeprazole but Not Pantoprazole is Associated with Lower Plasma Concentrations of Clopidogrel's Active Metabolite , 2011, The Annals of pharmacotherapy.
[4] P. D. de Groot,et al. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. , 2011, Blood.
[5] Junmei Chen,et al. Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. , 2010, Blood.
[6] C. Hirschhäuser,et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy , 2011, Nature Medicine.
[7] A. de Boer,et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. , 2010, European heart journal.
[8] F. Rosendaal,et al. The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE–Platelets project , 2010, Journal of thrombosis and haemostasis : JTH.
[9] V. Deneer,et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. , 2010, JAMA.
[10] A. de Boer,et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation , 2010, Pharmacogenetics and genomics.
[11] P. D. de Groot,et al. Staphylococcal superantigen‐like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibα and αIIbβ3 , 2009, Journal of thrombosis and haemostasis : JTH.
[12] F. Leebeek,et al. Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions , 2009, Circulation. Cardiovascular genetics.
[13] E. Antman,et al. Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.
[14] P. Mannucci,et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. , 2009, Blood.
[15] A. Franx,et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome , 2006, Journal of thrombosis and haemostasis : JTH.
[16] P. D. de Groot,et al. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. , 2005, Blood.